{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-102899","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.998311+00:00","generated_at":"2026-05-29T18:05:35.576581+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024","bullets":["Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.","Transition period covers July 1, 2024 through December 31, 2024.","Company will file Form 10-KT with audited financials for the transition period."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-102899","json":"https://secwatch.observer/filing/0001213900-24-102899.json","markdown":"https://secwatch.observer/filing/0001213900-24-102899.md","text":"https://secwatch.observer/filing/0001213900-24-102899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024102899/0001213900-24-102899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024102899/ea0222615-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:05:35.576581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}